Legal Representation
Attorney
Michael T. Olsen
USPTO Deadlines
Next Deadline
300 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-05-26)
Due Date
May 26, 2026
Grace Period Ends
November 26, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
37 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 26, 2025 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | Loading... |
| Jan 30, 2025 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... |
| Nov 20, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Sep 15, 2021 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Sep 15, 2021 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Sep 15, 2021 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Sep 15, 2021 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Sep 15, 2021 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Oct 17, 2020 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Sep 25, 2020 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Sep 25, 2020 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Aug 26, 2020 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| May 26, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 10, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 10, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 6, 2020 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Feb 28, 2020 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Feb 19, 2020 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Feb 19, 2020 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Feb 19, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 12, 2020 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Feb 12, 2020 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Jan 31, 2020 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 17, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 17, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 17, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 9, 2019 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jul 19, 2019 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Jul 19, 2019 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jun 27, 2019 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Jun 26, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 24, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 7, 2018 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 5, 2018 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 18, 2018 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Sep 13, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 6, 2018 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical and veterinary preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for use in the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for use in the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome
Classification
International Classes
005